arrow
V

Veit Bücklein

LMU University Hospital
H指数:31
被引数:3,461

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Consolidative allogeneic HCT vs. a watch-and-wait approach for B-cell acute lymphoblastic leukemia patients with early loss of B-cell aplasia after CAR T-cell therapy

巩固性同种异基因HCT与观察等待策略的比较:CAR T细胞治疗后早期丧失B细胞 aplasia的B细胞急性淋巴细胞白血病患者

2026-09-290
PRE
TP53-mutant CHIP defines a pro-inflammatory phenotype and predicts adverse outcomes after CAR T-cell therapy

TP53突变型CHIP定义了促炎表型并预测CAR T细胞疗法后的不良结局

Leukemia
IF13.4
2026-08-240
OAAI
TP53 deficiency in AML induces resistance to T-cell engagers through an immunosuppressive secretome

AML中TP53缺陷通过免疫抑制性分泌组诱导T细胞接合剂耐药性

Leukemia
IF13.4
2026-06-010
OAAI
Gastric and rectal administration of encorafenib with targeted chemotherapy against BRAF V600E-mutant rectal cancer with bowel obstruction

针对BRAF V600E突变型伴有肠梗阻的直肠癌,采用Encorafenib靶向化疗联合胃和直肠给药

2026-05-010
PRE
A randomized clinical study comparing trabectedin combined with regional hyperthermia with trabectedin in patients with advanced soft tissue sarcoma: HyperTET, a German Interdisciplinary Sarcoma Group trial

一项随机临床试验比较曲贝替定联合区域性高温疗法与曲贝替定在晚期软组织肉瘤患者中的疗效:HyperTET,一项德国多学科肉瘤组试验

2026-04-090
OAAI
Time-of-Day of CAR T-Cell Infusion and Outcomes in Large B-Cell Lymphoma

CAR T细胞输注的昼夜时间与弥漫性大B细胞淋巴瘤的结局

Blood
IF23.1
2025-12-260
OAAI
FLT3-directed BiTE Molecules versus CAR T Cells in AML: Co-stimulatory Signals Mitigate T-Cell Exhaustion

FLT3靶向BiTE分子与CAR T细胞在AML中的比较:共刺激信号缓解T细胞耗竭

2025-12-020
OAAI
Management of immune effector cell-associated neurotoxicity syndrome following CAR-T cell therapy in clinical practice: A multicentric, retrospective, real-world analysis of treatment approaches and outcomes

临床实践中CAR-T细胞疗法后免疫效应细胞相关神经毒性综合征的管理:一种多中心、回顾性、真实世界分析治疗方法和结局

2025-11-010
PRE
Prognostic Value of Inflammation-Based Scores in R/R LBCL Patients Treated with CD3xCD20 Bispecific T-Cell Engagers

炎症为基础评分在复发/难治性LBCL患者接受CD3xCD20双特异性T细胞接合物治疗中的预后价值

2025-10-240
OAAI
Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma

CD19 CAR-T在大型B细胞淋巴瘤中国际代谢预后指数的优化与验证

2025-08-260
OAAI
Liver-FDG-uptake augments early PET/CT prognostic value for CD19-targeted CAR-T cell therapy in diffuse large B cell lymphoma
2025-03-170
OAAI
Two-layered immune escape in AML is overcome by Fcγ receptor activation and inhibition of PGE2 signaling in NK cells

AML中的两层免疫逃逸被NK细胞中Fcγ受体的激活和PGE2信号通路的抑制所克服。

BLOOD
IF23.1
2025-01-211
OA
Prognostic significance of immune reconstitution following CD19 CAR T-cell therapy for relapsed/refractory B-cell lymphoma

CD19 CAR T细胞疗法后免疫重建的预后意义,针对复发/难治性B细胞淋巴瘤

2025-01-130
OAAI
Evolution of T-cell fitness through AML progression: enhanced bispecific T-cell engager-mediated function of bone marrow T cells at remission compared to initial diagnosis and relapse
LEUKEMIA
IF13.4
2024-08-221
OAAI
Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality

Car-t后将EHA/EBMT分级应用于ICAHT: 比较发病率以及与感染和死亡率的关联

2024-04-1010
OAAI
Friday Leukemia-a Structural Phenomenon
2024-02-090
OA